The mitogen-activated protein (MAP) kinases constitute a family of proline-directed serine/threonine kinases included in least four distinct cascades; extracellular -signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38 MAP kinase and ERK5. MAP kinases func tion as cellular signal transducers, and play a central role in the control of cellular proliferation, differentiation, and apoptosis in multicellular organisms. MAP kinase function has been analyzed in detail using commercially available low molecular weight compounds, which specif ically inhibit kinase-dependent signal transduction. The compounds of choice for many researchers are PD 98059 (1) and U0126 (2) , which demonstrate the participation of the ERK cascade in particular biological processes, and SB 202190 and SB 203580, which demonstrate the involvement of p38 MAP kinase (3) (4) (5) . Since an inhibitor specific for JNK (6) has also been developed recently, the function of MAP kinases in cellular signal transduction pathways involved in complex biological processes may become clearer.
In the course of studying cellular signal transduction in monocytic THP-1 cells (7), we found that SB 203580 significantly reinforced interleukin (IL)-l(3 and tumor necrosis factor a (TNF(x) gene expression induced by low concentrations of bufalin, a cardiotonic steroid that induces differentiation (8) and apoptosis (9) in leukemia cells. It would be interesting to determine the mechanism by which SB 203580 achieves these effects, since they have not been reported for other MAP kinase inhibitors. It has been shown, however, that in addition to p38 MAP kinase, SB 203580 binds to and inhibits c-Raf kinase in vitro (10 There was no sign of nuclear translocation of ERK under these experimental conditions (Fig. 3A) . To determine the nature of the relationship between the impaired nuclear translocation of ERK caused by SB 203580 and the inhibitory effect it has on p38 MAP kinase, we utilized recently developed SB 239063, a p38 MAP kinase inhibitor with greater selectivity (18) . SB 239063 showed no detectable effect on MEK and ERK phosphorylation or on the nuclear translocation of ERK (data not shown). However, SB 239063 did inhibit ERK nuclear translocation induced by TPA almost completely, indicating that inhibition of p38 MAP kinase activity causes impaired ERK translocation (Fig. 3B) .On the other hand, SB203580, which induces the activities of the ERK cascade in addition to its inhibitory effect on p38 MAP kinase, had little effect on TPA-mediated ERK nuclear translocation (Fig. 3B) . It is widely known that SRE is activated in an ERKdependent manner through the phosphorylation of ter nary complex factors such as Elk-1 (19, 20) . Therefore, we utilized a SRE-dependent reporter assay system to dem onstrate the regulation of the ERK function by p38 MAP kinase activity. The luciferase activity in THP-1 cells transfected with the reporter gene was induced by TPA and this response was cancelled by pretreatment of the cells with PD98059 (Fig. 4A) , an inhibitor of MEK, indi cating that the TPA-mediated increase in luciferase activity is mainly mediated through ERK-dependent sig nal transduction.
Co-transfection with the p38 T180A and Y182F double mutant, whicc is known to disturb the p38 activity in a dominant negative manner (14) , sup pressed TPA-induced luciferase activity in a transfected DNA amount-dependent manner (Fig. 4B) , although the observed net inhibitory effect was not high. Because the transfection efficiency and the expression level of the exogenously introduced gene were very low in THP-1 cells, we next utilized COS-7 cells, which are widely used for experiments on ectopic expression. In COS-7 cells, expression of the dominant negative mutant of p38 MAP kinase efficiently inhibited TPA-induced transactiva tion. This effect was observed in a transfected DNA amount-dependent manner and almost complete inhibi tion was observed with the highest DNA amount (Fig.  4C) . On the other hand, co-transfection of wild type p38 MAP kinase had no effect on the SRE-dependent transac tivation (data not shown).
DISCUSSION
It has been reported that treatment of cells with c-Raf inhibitors such as SB 203580 and ZM 336372 paradoxi cally induces kinase activation (10, 11) . This phenome non is explained by a putative negative feedback mecha nism in which c-Raf activity is suppressed by its own kinase activity. Cutting the negative feed back loop by means of inhibitors allows accumulation of the active form, resulting in a striking increase in the kinase activ ity, when measured in the absence of the inhibitor in vitro (11 MSK1 (27) , and PRAK (28), the potential for cross-talk between the MAP kinases that regulate their intracellu lar distribution is a novel idea and should be examined carefully in further studies. In addition, results in a recent report that p38 MAP kinase activity is required for AP-1-dependent transactivation elicited by TPA in THP-1 cells (29) are entirely consistent with the present study. However, this report demonstrates that p38 MAP kinase regulates AP-1-driven transcription, in part, by modulating the activation of the basal transcriptional module. In conjunction with our present results, it is, therefore, suggested that p38 MAP kinase modulates ERK-mediated signal transduction at multiple steps.
In conclusion, the present study demonstrates that SB 203580 activates the ERK cascade without transducing the signal into the nucleus. However, the impaired ERK signal transduction caused by the inhibitor may turn over and lead to synergistic enhancement of ERK cas cade-dependent gene expression, when cells are treated in conjunction with other stimulants, such as bufalin (7) . Consequently, care should be taken when applying p38 MAP kinase inhibitors (particularly compounds with affinity to c-Raf) to the treatment of inflammatory dis eases.
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